Powered by
ANN ARBOR–HistoSonics, developers of non-invasive sonic beam therapy called histotripsy, announced that the U.S. Food and Drug Administration has approved the company sponsored #HOPE4KIDNEY Trial, which is designed to evaluate the …
ANN ARBOR—HistoSonics Inc., developer of a non-invasive sonic beam therapy, announced that it has raised $85 million in a financing led by Johnson & Johnson Innovation Inc., with participation from …
ANN ARBOR–Endra Life Sciences Inc. (Nasdaq: NDRA), developers of Thermo Acoustic Enhanced UltraSound (TAEUS) medical diagnostic technology, announced that it will be effecting a reverse stock split of its outstanding …
DETROIT–The Barbara Ann Karmanos Cancer Institute, a National Cancer Institute-Designated Comprehensive Cancer Center, has become the first cancer center to receive the SoftVue 3D Whole Breast Ultrasound Tomography System following …
ANN ARBOR–Endra Life Sciences Inc. (NASDAQ: NDRA), the Ann Arbor-based ultrasound technology developer, has won two new patents from the United States Patent and Trademark Office. They are U.S. Patent …
ANN ARBOR—HistoSonics, developer of a non-invasive sonic beam therapy, announced today the treatment of the first patient in the #HOPE4LIVER US Study. The investigational device study was approved by the …
ANN ARBOR—HistoSonics Inc. announced that it had received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new technology, …